International, Multicenter, Randomized, Double-blind, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GNR-067 and Lucentis® in Patients With Neovascular (Wet) Age-related Macular Degeneration
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms NAP
- Sponsors GENERIUM Pharmaceuticals
Most Recent Events
- 15 Sep 2023 Planned primary completion date changed from 15 Aug 2023 to 15 Aug 2024.
- 02 Aug 2022 Status changed from not yet recruiting to recruiting.
- 21 Jan 2022 Planned initiation date changed from 15 Dec 2021 to 20 Mar 2022.